News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Julio Chavez, MD, Moffitt Cancer Center

Articles by Julio Chavez, MD, Moffitt Cancer Center

Treatment of R/R DLBCL: Beyond CAR T Therapy

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

Phase 2B SADAL Trial in R/R DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

RE-MIND Study in R/R DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

L-MIND Study in R/R DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

CAR T in Transplant-Eligible and Transplant-Ineligible DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

Standard of Care for Relapsed/Refractory DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

Novel Therapies: R2-GDP-GOTEL and Smart Start

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Novel Treatment Combinations for R/R DLBCL

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Relapsed/Refractory DLBCL: Unmet Needs

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Emerging Treatments for Relapsed/Refractory DLBCL

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

SADAL Trial Regimen FDA Approval

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

SADAL Trial Overview

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

CAR T-Cell Therapy Clinical Trials

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

CAR T-Cell Therapy Response Rates

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

CAR T Cell Therapy in Relapsed/Refractory DLBCL

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Relapsed/Refractory DLBCL Treatment Landscape

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

R/R DLBCL: Transplant Eligibility and R-CHOP

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Newly Diagnosed DLBCL: Treatment Decision Factors

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

DLBCL Risk Assessment and Genetic Signatures

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Therapy Initiation Prior to Cytogenetic Testing Results

ByBrian Hill, MD, PhD, Cleveland Clinic,Andre Goy, MD, John Theurer Cancer Center,Julio Chavez, MD, Moffitt Cancer Center,Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 17th 2020

Latest Updated Articles

SADAL Trial Overview
Published: July 17th 2020 | Updated:
CAR T-Cell Therapy Clinical Trials
Published: July 17th 2020 | Updated:
DLBCL Risk Assessment and Genetic Signatures
Published: July 17th 2020 | Updated:
CAR T in Transplant-Eligible and Transplant-Ineligible DLBCL
Published: September 22nd 2020 | Updated:
Therapy Initiation Prior to Cytogenetic Testing Results
Published: July 17th 2020 | Updated:
$CAR T Cell Therapy in Relapsed/Refractory DLBCL$
CAR T Cell Therapy in Relapsed/Refractory DLBCL
Published: July 17th 2020 | Updated:

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma